Observed Differences of Select ARs Between TECENTRIQ + Avastin^® (bevacizumab) vs Sorafenib

ARs occurring at a frequency of ≥10% in patients in either arm and ≥5% difference between arms ^1,3*

1L=first line; ALT=alanine aminotransferase; AR=adverse reaction; mHCC=metastatic hepatocellular carcinoma; PPE=palmar-plantar erythrodysesthesia.
*Graded per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0).
^†Includes fatigue and asthenia.

Consider how certain ARs can impact your 1L unresectable or mHCC patients
 

• Treatment-related grade 3 to 4 ARs were 36% with TECENTRIQ + Avastin vs 46% with sorafenib ^1,7
  • The most common grade 3 to 4 ARs (≥2%) were hypertension, proteinuria, infusion-related reaction, and fatigue/asthenia
    

Established safety profile

Additional ARs occurring at a frequency of ≥10% in patients receiving TECENTRIQ + Avastin ¹

Additional safety data reported in IMbrave150 ^1,3

• The proportion of patients experiencing grade 3 to 4 bleed rates was 6.4% with TECENTRIQ + Avastin and 5.8% with sorafenib
  • The majority of bleeding/hemorrhage AEs were grade 1 to 2
• 4.6% of patients who were treated with TECENTRIQ + Avastin experienced fatal ARs. The most common ARs leading to death were gastrointestinal and esophageal varices hemorrhage (1.2%) and infections (1.2%)
  
• Serious ARs occurred in 38% of patients treated with TECENTRIQ + Avastin
  
  • The most frequent (≥2%) were gastrointestinal hemorrhage (7%), infections (6%), and pyrexia (2.1%)
    
• ARs leading to discontinuation of TECENTRIQ occurred in 9% of patients in the TECENTRIQ + Avastin arm vs 10% with sorafenib
  
  • The most common ARs leading to discontinuation of TECENTRIQ were hemorrhages (1.2%), including gastrointestinal, subarachnoid, and pulmonary hemorrhages; increased transaminases or bilirubin (1.2%); infusion-related reaction/cytokine release syndrome (0.9%); and autoimmune hepatitis (0.6%)
    
• ARs leading to interruption of TECENTRIQ + Avastin occurred in 41% of patients
  
  • The most common (≥2%) were liver function laboratory abnormalities including increased transaminases, bilirubin, or alkaline phosphatate (8%); infections (6%); gastrointestinal hemorrhages (3.6%); thrombocytopenia/decreased platelet count (3.6%); hyperthyroidism (2.7%); and pyrexia (2.1%)
    
• Immune-related ARs requiring systemic corticosteroid therapy occurred in 12% of patients in the TECENTRIQ + Avastin arm
  

AE=adverse event; AR=adverse reaction.

Laboratory abnormalities worsening from baseline occurring in ≥20% of patients receiving TECENTRIQ + Avastin ¹

Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: TECENTRIQ plus bevacizumab (222-323) and sorafenib (90-153).
AST=aspartate aminotransferase.